Capmatinib Hydrochloride Patent Expiration
Capmatinib Hydrochloride is Used for treating patients with metastatic non-small cell lung cancer with a mesenchymal-epithelial transition exon 14 skipping mutation. It was first introduced by Novartis Pharmaceutical Corp
Capmatinib Hydrochloride Patents
Given below is the list of patents protecting Capmatinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tabrecta | US10596178 | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide | Jul 22, 2035 | Novartis Pharm |
| Tabrecta | US7767675 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Nov 19, 2032 | Novartis Pharm |
| Tabrecta | US8420645 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | Jun 05, 2031 | Novartis Pharm |
| Tabrecta | US8901123 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | May 20, 2029 | Novartis Pharm |
| Tabrecta | US12084449 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Nov 19, 2027 | Novartis Pharm |
| Tabrecta | US8461330 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Nov 19, 2027 | Novartis Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Capmatinib Hydrochloride's patents.
Latest Legal Activities on Capmatinib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Capmatinib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 18 Apr, 2024 | US7767675 |
| Notice of Final Determination -Election Required | 18 Apr, 2024 | US8420645 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 08 Dec, 2023 | US7767675 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 08 Dec, 2023 | US8420645 |
| Email Notification Critical | 20 Nov, 2023 | US8461330 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Nov, 2023 | US8901123 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Nov, 2023 | US8461330 |
| Email Notification Critical | 20 Nov, 2023 | US8901123 |
| Email Notification Critical | 19 Sep, 2023 | US7767675 |
| Change in Power of Attorney (May Include Associate POA) Critical | 19 Sep, 2023 | US8420645 |
Capmatinib Hydrochloride's Family Patents
